Slate Therapeutics
About
What does Slate Therapeutics do?
Slate Therapeutics is focused on developing an innovative drug-device combination product designed to treat chronic sinusitis. Their vision is to enable sinusitis patients to heal faster, better, and for longer periods, aiming to overcome the limitations of existing alternative treatments by providing a durable therapeutic solution.
Where is Slate Therapeutics headquartered?
Slate Therapeutics is headquartered in San Diego, United States.
When was Slate Therapeutics founded?
Slate Therapeutics was founded in 2021.
What industry does Slate Therapeutics operate in?
Slate Therapeutics operates in Healthcare, Medical Device, MedTech, HealthTech, Drug Discovery, Chronic Sinusitis Treatment.
What is Slate Therapeutics's current status?
Slate Therapeutics's current operating status is: Inactive.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Your health consultation for a pain-free life, offering pain management and therapy solutions.
An AI-powered platform for cancer patients and survivors in Asia to navigate care and understand their diagnosis.
AI-powered personalized sleep coaching and actionable insights for improving sleep quality.
SomaIQ drafts the interpretation and patient explanation for your review, reducing a 90-minute task to five.
AI-powered digital health platform offering personalized nutrition and wellness plans based on individual metabolism.
Akylmed is developing an AI-powered platform to streamline medical documentation and administrative tasks for healthcare providers.
An entrant is a company tagged MedTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 1 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.